Several months after acquiring the rights to TNX-1900 oxytocin nasal spray for the treatment of migraine headaches from Trigemina, Tonix Pharmaceuticals announced that it has acquired an exclusive license to technology from the University of Geneva for the use of oxytocin to treat insulin resistance and related conditions such as obesity. The company has not yet submitted an IND for TNX-1900. The purpose of acquiring the University of Geneva technology, Tonix said, is to allow the company to develop TNX-1900 for additional indications, including insulin resistance, impaired glucose tolerance, and obesity.
Tonix Pharmaceuticals President and CEO Seth Lederman said, “The important new technology from University of Geneva will allow Tonix to develop intranasal oxytocin on a broader platform to treat both central nervous system (CNS) and cardiometabolic conditions. We believe that TNX-1900 has the potential to be a safe, natural, non-addictive, and easy to administer treatment alternative for a number of CNS disease states. Our lead indication for TNX-1900 is for the treatment of migraine . . . . The effects of intranasal oxytocin on improving peripheral insulin sensitivity, pancreatic function and lipid metabolism encourage us to develop TNX-1900 as a potential therapeutic in obesity, insulin resistance, diabetes management and related metabolic complications.”
Read the Tonix Pharmaceuticals press release.
